BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameJean-Christophe May
2.Reason for the notification
a)Position/statusExecutive Vice President and Chief Commercial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Shares





DK0015998017
b)Nature of the transactionExercise of warrants
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 155.809,000
d)Aggregated information
  • Aggregated volume
  • Price
 



9,000

DKK 1,402,200.00
e)Date of the transaction2023-05-23
f)Place of the transactionNasdaq Copenhagen A/S, XCSE



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameJean-Christophe May
2.Reason for the notification
a)Position/statusExecutive Vice President and Chief Commercial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Shares





DK0015998017
b)Nature of the transactionSale
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 207.389,000
d)Aggregated information
  • Aggregated volume
  • Price
 



9,000

DKK 1,866,394.80
e)Date of the transaction2023-05-23
f)Place of the transactionNasdaq Copenhagen A/S, XCSE

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance the public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. Using our live virus vaccine platform technology, MVA-BN® and in-licensed technologies, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 22 / 2023

Attachment



EN
23/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Consortium consisting of Nordic Capital and Permira receives final reg...

Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholders of Bavarian Nordic NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 9 October, 2025 – With reference to the announcements of 26 August 2025 (no. 24/2025 and no. 25/2025) and the announcement of 29 September 2025 (no. 27/2025) concerning the all-cash voluntary recommended public takeover...

 PRESS RELEASE

Konsortium bestående af Nordic Capital og Permira modtager den sidste ...

Konsortium bestående af Nordic Capital og Permira modtager den sidste regulatoriske godkendelse i forhold til overtagelsestilbuddet til aktionærerne i Bavarian Nordic MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 9. oktober 2025 – Med henvisning til selskabsmeddelelserne af 26. august 2025 (nr. 24/2025 og 25/2025) og selskabsmeddelelsen af 29. september 2025 (nr. 27/2025) vedrørende det kontante friv...

 PRESS RELEASE

Bavarian Nordic rapporterer positive toplinjeresultater for mpox-/kopp...

Bavarian Nordic rapporterer positive toplinjeresultater for mpox-/koppevaccine i børn Det primære endemål blev opnået i det kliniske forsøg, som viste sammenlignelige sikkerhedsdata og immunresponser for MVA-BN mellem børn i alderen 2-11 år og voksne.Resultaterne vil understøtte en ansøgning om udvidelse af indikationen hos EMA i 2026. KØBENHAVN, Danmark, 7. oktober 2025 – Bavarian Nordic A/S (OMX: BAVA) rapporterede i dag toplinjeresultater fra et klinisk forsøg med selskabets MVA-BN® mpox-/koppevaccine i børn i alderen 2 til 11 år. Forsøget () inkluderede 460 personer fordelt pi to grup...

 PRESS RELEASE

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccin...

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population Primary endpoint was met in clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults.Results will support filing for label extension with EMA in 2026. COPENHAGEN, Denmark, October 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a clinical study of its MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age. The study () enrolled 460 individuals in two cohorts: child...

 PRESS RELEASE

Konsortium bestående af Nordic Capital og Permira forlænger tilbudsper...

Konsortium bestående af Nordic Capital og Permira forlænger tilbudsperioden til 14. oktober 2025 og giver en opdatering vedrørende de regulatoriske godkendelser i forhold til overtagelsestilbuddet til aktionærerne i Bavarian Nordic MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 29. september 2025 – Med henvisning til selskabsmeddelelsen af 26. august 2025 (nr. 24/2025) angående offentliggørelsen af ti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch